Aarti Drugs Ltd
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]
It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]
- Market Cap ₹ 3,894 Cr.
- Current Price ₹ 424
- High / Low ₹ 635 / 420
- Stock P/E 25.6
- Book Value ₹ 139
- Dividend Yield 0.24 %
- ROCE 15.0 %
- ROE 13.9 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 10.1% over past five years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 5.15% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -4.48%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Part of BSE Allcap BSE SmallCap BSE Healthcare Nifty Microcap 250 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
479 | 501 | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,716 | 2,529 | 2,380 | |
396 | 432 | 925 | 960 | 1,005 | 1,042 | 1,350 | 1,541 | 1,714 | 2,156 | 2,407 | 2,208 | 2,092 | |
Operating Profit | 83 | 69 | 172 | 180 | 190 | 202 | 211 | 266 | 440 | 333 | 309 | 321 | 288 |
OPM % | 17% | 14% | 16% | 16% | 16% | 16% | 14% | 15% | 20% | 13% | 11% | 13% | 12% |
0 | 0 | 1 | 0 | 4 | 1 | 6 | 6 | 5 | 11 | 2 | 4 | 5 | |
Interest | 19 | 17 | 42 | 48 | 40 | 38 | 44 | 37 | 26 | 24 | 37 | 38 | 34 |
Depreciation | 17 | 19 | 31 | 37 | 38 | 40 | 43 | 49 | 50 | 50 | 50 | 51 | 53 |
Profit before tax | 47 | 33 | 100 | 95 | 116 | 125 | 131 | 185 | 369 | 270 | 224 | 236 | 206 |
Tax % | 40% | 29% | 23% | 28% | 29% | 34% | 32% | 24% | 24% | 24% | 26% | 27% | |
29 | 24 | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | 166 | 172 | 152 | |
EPS in Rs | 2.92 | 2.46 | 7.97 | 7.09 | 8.57 | 8.73 | 9.52 | 15.17 | 30.09 | 22.14 | 17.96 | 18.65 | 16.57 |
Dividend Payout % | 21% | 25% | 41% | 24% | 3% | 3% | 3% | 3% | 8% | 5% | 6% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 5% |
TTM: | -12% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | -15% |
TTM: | -16% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 26% |
3 Years: | -7% |
1 Year: | -15% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 16% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 |
Reserves | 134 | 151 | 284 | 333 | 376 | 432 | 520 | 629 | 820 | 944 | 1,100 | 1,190 | 1,186 |
189 | 267 | 448 | 483 | 480 | 546 | 507 | 389 | 351 | 543 | 609 | 564 | 590 | |
84 | 93 | 248 | 261 | 311 | 388 | 405 | 535 | 502 | 629 | 620 | 587 | 562 | |
Total Liabilities | 419 | 523 | 1,004 | 1,102 | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,430 |
208 | 248 | 448 | 493 | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 838 | |
CWIP | 3 | 10 | 16 | 34 | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 299 |
Investments | 2 | 5 | 5 | 5 | 12 | 11 | 12 | 13 | 17 | 19 | 19 | 20 | 20 |
206 | 260 | 534 | 570 | 584 | 748 | 785 | 907 | 1,064 | 1,422 | 1,516 | 1,340 | 1,273 | |
Total Assets | 419 | 523 | 1,004 | 1,102 | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,430 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
59 | 21 | 105 | 133 | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 | |
-30 | -76 | -107 | -99 | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 | |
-24 | 53 | 1 | -33 | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 | |
Net Cash Flow | 5 | -3 | -1 | 1 | -0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 88 | 88 | 105 | 106 | 91 | 110 | 107 | 99 | 94 | 110 | 116 | 102 |
Inventory Days | 77 | 103 | 82 | 86 | 100 | 132 | 86 | 102 | 117 | 115 | 101 | 107 |
Days Payable | 60 | 73 | 83 | 90 | 94 | 123 | 85 | 104 | 93 | 103 | 94 | 94 |
Cash Conversion Cycle | 105 | 118 | 104 | 103 | 97 | 119 | 109 | 97 | 118 | 123 | 123 | 115 |
Working Capital Days | 106 | 134 | 98 | 102 | 97 | 122 | 105 | 87 | 110 | 122 | 126 | 116 |
ROCE % | 20% | 13% | 18% | 18% | 17% | 17% | 21% | 34% | 21% | 15% | 15% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
15 Dec - Intimation of loss of share certificates and issuance of duplicates.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
6 Dec - Intimation of loss of share certificates and issuance of duplicates.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
6 Dec - Intimation of loss of share certificate and issuance of duplicate.
-
Announcement under Regulation 30 (LODR)-Acquisition
27 Nov - Incorporation of Pharma Go SpA as a step down subsidiary.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
27 Nov - Issuance of duplicate share certificates to shareholders.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Sep 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Sep 2023TranscriptNotesPPT
-
Jul 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
May 2020TranscriptPPT
-
May 2019TranscriptNotesPPT
Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]